Trial Profile

An early access program of Endari in patients with sickle cell disease

Status: Planning

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 21 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glutamine (Primary)
Indications Sickle cell anaemia
Focus Expanded access; Therapeutic Use

Most Recent Events

21 Jun 2021 According to an Emmaus Life Sciences media release, the company has received confirmation from the Swiss Agency for Therapeutic Products (Swissmedic) for Marketing Authorization (MA) for Endari in Switzerland. The company will provide Endari to sickle cell disease patients on an early access basis during the review and approval process.
21 Jun 2021 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com